Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term extension study of KT-621 in asthma
2026-526241-98-00Phase 2Authorised
- Sponsor
- Kymera Therapeutics
- Start
- Sep 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of KT-621 in eosinophilic asthma (EA), sponsored by Kymera Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events and Incidence of treatment-emergent serious adverse events. Planned start Sep 2026; status: authorised.
02
Drugs
KT-621
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on 2026-526241-98-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526241-98-00.